丹槐银屑浓缩丸对银屑病模型兔血管内皮生长因子及其受体表达的影响

目的：观察丹槐银屑浓缩丸对日本大耳白兔实验性银屑病血管内皮生长因子(vascular endothelial growthfactor, VEGF)及其受体表达的影响。方法将42只健康日本大耳白兔按随机数字表法分为空白对照组，模型组，阿维A组，丹槐银屑浓缩丸小、中、大剂量组，除空白对照组外，其余各组均于兔耳背侧涂5％普萘洛尔溶液4周造模，空白对照组耳背侧涂生理盐水。造模成功后1 d，阿维A组灌胃1%阿维A胶囊溶液；丹槐银屑浓缩丸小、中、大剂量组分别灌胃丹槐银屑浓缩丸混悬液20、40、80 mg/kg；空白对照组和模型组灌胃等体积生理盐水，各组均给药1次/d，连续给药4周。采用ELISA法测定给药前后耳病变组织VEGF及其受体1(FLT-1)、受体2(KDR)蛋白表达，采用PCR检测给药前后耳病变组织VEGF mRNA表达，测定耳病变组织真皮乳头血管密度(microvessel density, MVD)、外周血T淋巴细胞增殖。结果与模型组比较，丹槐银屑浓缩丸中、大剂量组 VEGF 蛋白(114.43±9.52)ng/ml、(109.65±9.15)ng/ml比(179.90±11.30)ng/ml]、VEGF mRNA(0.83±0.07)、(0.80±0.06)比(2.74±0.15)]、FLT-1(4.54±0.26)ng/ml、(4.16±0.24)ng/ml 比(6.92±0.38)ng/ml]、KDR(2.48±0.16)ng/ml、(2.51±0.19)ng/ml比(6.79±0.27)ng/ml]、MVD(10.12±1.97)、(9.83±1.12)比(16.45±2.05)]表达及外周血T淋巴细胞增殖(87.35±6.29)%、(86.21±6.42)%比(123.74±9.18)%]均明显降低(P＜0.05)。结论丹槐银屑浓缩丸可降低VEGF过度表达，阻断VEGF与其受体结合，抑制病变组织皮下血管新生、重建，降低真皮乳头微血管的异常增生，抑制T细胞增殖。

Effect ofDanhuai-Yinxiecondensed pill on the expression of VEGF and its receptors in the model rabbits with psoriasis

Objective To observe the effect ofDanhuai-Yinxie condensed pill on the expression of VEGF and its receptors in the model rabbits with psoriasis.Methods Fourty-two healthy Japanese white rabbits were randomly divided into the control group, the model group, the Acitretin group, and the low-, medium- and high-doses ofDanhuai-Yinxie condensed pill groups. The backs of rabbits’ ears were wiped with 5% propranolol for 4 weeks in the latter four groups, while with saline for the same period in the control group. The rabbits in the Acitretin group were intragastric administrated with 1% Acitretin one day since the models of psoriasis were successed, while the rabbits in the low-, medium- and high-doses ofDanhuai-Yinxie condensed pill groups were intragastric administrated withDanhuai-Yinxie suspension 20, 40, 80 mg/kg daily, respectively. The rabbits in the control and model groups were intragastric administrated with equal-volume saline daily. The expression of VEGF, its receptor 1 (FLT-1) and receptor 2 (KDR) were detected by ELISA method, and the expression of VEGF mRNA was detected by PCR method, dermal papillary vascular density (MVD) and the T lymphocytes proliferation from peripheral blood were detected.Results The expression of VEGF (114.43 ± 952 ng/ml, 109.65 ± 9.15 ng/mlvs. 179.90 ± 11.30 ng/ml), VEGF mRNA (0.83 ± 0.07, 0.80 ± 0.06vs. 2.74 ±  0.15), FLT-1 (4.54 ± 0.26 ng/ml, 4.16 ± 0.24 ng/mlvs. 6.92 ± 0.38 ng/ml), KDR (2.48 ± 0.16 ng/ml, 2.51 ± 0.19 ng/mlvs. 6.79 ± 0.27 ng/ml), MVD (10.12 ± 1.97, 9.83 ± 1.12vs. 16.45 ± 2.05) and T lymphocytes proliferation (87.35% ± 6.29%, 86.21% ± 6.42%vs. 123.74% ± 9.18%) in the medium- and the high-dose groups significant decreased than those in the model group (P<0.05).ConclusionDanhuai-Yinxiecondensed pill could reduce the expression of VEGF, block the binding of VEGF to its receptors, inhibit angiogenesis, inhibit the reconstruction of subcutaneous tissues, reduce the dysplasia of dermal microvessels, and inhibit the proliferation of T cells.